Safety and Immune Response to Autologous Dendritic Cells Transduced with Ad-GMCAIX
Official Title of Study: A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells transduced with Ad-GMCAIX in patients with metastatic renal cell carcinoma.
Objective of the study (lay terms): The research being conducted is Phase 1 immunotherapy trial. A Phase 1 trial is the first testing of an experimental treatment in humans. The purpose of a Phase 1 study is to determine what happens when an experimental treatment is given to humans, for example, how the body reacts to the treatment and what kinds of side effects, if any, occur. This study is not designed to improve your health or well-being.
For More Detailed Information, Contact: